Ensysce Biosciences, Inc.
ENSCHealthcare|Biotechnology|US
$0.33
-0.03 (-8.95%)
DCF Value
$0.06
Cash / Share
$0.05
Clinical Trials (9)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT06602271 PF614 Analgesic Activity in Acute Postoperative Pain (PF614-301) | Postoperative Pain, Acute | P3 | Recruiting | 320 | RCT, Double-blind | PF614 capsule, Placebo |
| NCT06500793 Single Dose Study, Pharmacokinetics of Oxycodone and PF614 Co-Administered With Nafamostat (PF614-MPAR-102) | Pharmacokinetics, Healthy Volunteer | P1 | Recruiting | 54 | Open-label | PF614 capsule, Nafamostat Mesylate |
| NCT06629402 Assessment of PF614 Effects on Experimental Pain in the Cold Pressure Test (PF614-201) | Acute Pain | P2 | Completed | 16 | RCT, Double-blind | PF614, Placebo |
| NCT02454712 Study of PF614 Compared to OxyContin® in Healthy Volunteers (PF614-101) | Healthy | P1 | Completed | 64 | RCT, Open-label | PF614, Oxycodone extended-release, Naltrexone Hydrochloride |
| NCT05090280 Pharmacokinetics of Oxycodone and PF614 Co-Administered with Nafamostat (PF614-MPAR-101) | Pharmacokinetics | P1 | Completed | 111 | RCT, Open-label | PF614 solution, Naltrexone Hydrochloride, Nafamostat Mesylate |
| NCT05043766 Evaluation of Oral PF614 Relative to OxyContin (PF614-102) | Healthy Volunteers | P1 | Completed | 84 | RCT, Open-label | PF614, Naltrexone Hydrochloride, OxyContin |
| NCT04406415 Oral Nafamostat in Healthy Volunteers (NAF-101) | Pharmacokinetics | P1 | Completed | 17 | RCT, Single-blind | Nafamostat Mesilate, Placebo |
| NCT05567354 A Study to Evaluate the Intranasal Abuse Potential of PF614 in Non-Dependent Recreational Opioid Users (PF614-103) | Recreational Drug Use | P1 | Completed | 27 | RCT, Double-blind | PF614, Oxycodone |
| NCT05571345 A Study to Evaluate the Oral Abuse Potential of PF614 in Non-Dependent Recreational Opioid Users (PF614-104) | Recreational Drug Use | P1 | Completed | 32 | RCT, Double-blind | PF614, Oxycodone Hydrochloride 40 mg, Placebo |